Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation
- 28 Downloads
Cyclosporine (Cy) binds to lipoproteins in plasma. In order to test if its pharmacokinetics would be modified when efficient lipid-lowering treatment is introduced, a study has been done of Cy pharmacokinetics and any interaction with the lipid-lowering agent fenofibrate in hyperlipidaemic long-term, survivors of heart transplantation. Fenofibrate 200 mg once daily significantly reduced blood lipids (cholesterol 6.5 vs 7.7 mmol/l; apoprotein B 1.2 vs 1.6 g/l) but did not modify mean whole blood Cy trough levels (113 before fenofibrate vs 103 ng·ml−1), Cmax (812 ng·ml−1 by RIA and 757 ng·ml−1 by HPLC before fenofibrate versus 865 and 741 respectively, during fenofibrate); tmax (1.6 and 1.7 h before fenofibrate versus 1.4 and 1.4 h respectively), and t1/2 (13.9 and 11.1 h versus 9.5 and 10.7 h).
The only adverse effect was an increase in creatinine (157 vs 145 mmol/l). Further studies are needed to investigate the mechanism of Cy-fenofibrate nephrotoxicity and to evaluate the long-term efficiency and safety of fenofibrate after heart transplantation.
Key wordsCyclosporine Hyperlipidaemia heart transplantation fenofibrate fenofibric acid pharmacokinetics drug interaction nephrotoxicity
Unable to display preview. Download preview PDF.
- 7.De Lorgeril M, Dureau G, Guidollet J, Boissonnat P, Renaud S (1990) Prevalence of dyslipidemia in long-term survivors of heart transplantation. Eur Heart J 11: 176Google Scholar
- 10.Lemaire M, Tillement JP (1982) Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharmacol 34: 715–718Google Scholar
- 12.Brown WV, Dujovne CA, Farquhar JW, Feldman EB, Grundy SM, Knopp RH, Lasser NL, Mellies MJ, Palmer RH, Samuel P, Schonfeld G, Superko HR (1986) Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis 6: 670–678PubMedGoogle Scholar
- 13.Bizollon CA, Cohen R (1990) French interlaboratory cyclosporine quality assesment scheme. Nucl Med Biol 17: 737–744Google Scholar
- 18.Critical issues in cyclosporine monitoring: report of the task force on cyclosporine monitoring (1987) Clin Chem 33: 1269–1288Google Scholar
- 19.Venkataramanan R, Burckart GJ, Ptachcinski RJ, Lee A, Hardesty RL, Griffith BP (1986) Cyclosporine pharmacokinetics in heart transplant recipients. Transplant Proc 4: 768–770Google Scholar
- 21.Lindholm A, Henricsson S, Gang P (1988) The free fraction of cyclosporine in plasma: clinical findings with a new method. Transplant Proc 20: 377–381Google Scholar
- 23.Kunzendorf U, Brockmöller J, Jochimsen F, Roots I, Offermann G (1989) Immunosuppressive properties of cyclosporine metabolites. Lancet 1: 734–735Google Scholar
- 25.Kobashigawa JA, Murphy FL, Stevenson LW et al. (1990) Lowdose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 82 [Suppl IV]: IV 281-IV 283Google Scholar